Literature DB >> 3040851

Corticotropin releasing hormone stimulation test: diagnostic aspects in Cushing's syndrome.

M Boscaro, A Rampazzo, N Sonino, G Merola, M Scanarini, F Mantero.   

Abstract

The effect of exogenous ovine Corticotropin-Releasing Hormone (oCRH) on plasma ACTH and cortisol levels was investigated in 10 normal volunteers and in 37 patients with Cushing's syndrome (26 with pituitary-dependent disease, 5 with an adrenal adenoma, 2 with an adrenal carcinoma and 4 with bilateral nodular hyperplasia). In all normal subjects and in patients with Cushing's disease, oCRH 100 micrograms as a bolus produced an increase in both plasma ACTH and cortisol. The peak of ACTH occurred after 15-30 min, while plasma cortisol showed highest levels between 30 and 60 min after oCRH administration. The hormonal response in Cushing's disease showed great variability with a clear hyperresponsiveness at least in 6 out of 26 patients with Cushing's disease. A slight and delayed response occurred in 3 cases of bilateral nodular adrenal hyperplasia, while a fourth case showed hyperresponsiveness similar to that found in pituitary-dependent Cushing's disease. No response was observed in patients with an adrenal tumor. Eleven patients with Cushing's disease were tested before and 1 month after pituitary microadenomectomy. After surgery basal cortisol levels were reduced in 10 and became unresponsive or less responsive to oCRH. ACTH patterns were variable with a normal response only in few cases. Although this test seems of limited value in the diagnosis of hypercortisolism, it is a useful tool to differentiate some types of Cushing's syndrome (adrenal tumor from pituitary-dependent Cushing's disease). Variable patterns of response in cases with bilateral nodular adrenal hyperplasia limit the usefulness of this test in recognizing this rare form of hypercortisolism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3040851     DOI: 10.1007/BF03348134

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  23 in total

1.  CUSHING'S SYNDROME: NODULAR CORTICAL HYPERPLASIA OF ADRENAL GLANDS WITH CLINICAL AND PATHOLOGICAL FEATURES SUGGESTING ADRENOCORTICAL TUMOR.

Authors:  M A KIRSCHNER; R D POWELL; M B LIPSETT
Journal:  J Clin Endocrinol Metab       Date:  1964-10       Impact factor: 5.958

2.  Physiological dosing of exogenous ACTH.

Authors:  M L Graybeal; V S Fang
Journal:  Acta Endocrinol (Copenh)       Date:  1985-03

3.  The effect of ovine corticotrophin releasing factor (oCRF), bromocriptine and TRH on the secretion of ACTH and alpha-MSH in Nelson's syndrome and Cushing's disease.

Authors:  R R Abraham; E A Campbell; B Gillham; A J Thody; A R Altaher; A Prysor-Jones; V Wynn; M T Jones; J Jenkins
Journal:  Clin Endocrinol (Oxf)       Date:  1986-07       Impact factor: 3.478

4.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.

Authors:  W Vale; J Spiess; C Rivier; J Rivier
Journal:  Science       Date:  1981-09-18       Impact factor: 47.728

5.  Regulation of corticotropin-releasing factor (CRF) receptors in the rat pituitary gland: effects of adrenalectomy on CRF receptors and corticotroph responses.

Authors:  P C Wynn; J P Harwood; K J Catt; G Aguilera
Journal:  Endocrinology       Date:  1985-04       Impact factor: 4.736

6.  Corticotropin-releasing factor (CRF): stimulation in normal controls and in patients with Cushing's syndrome.

Authors:  O A Müller; J Hartwimmer; A Hauer; T Kaliebe; J Schopohl; G K Stalla; K von Werder
Journal:  Psychoneuroendocrinology       Date:  1986       Impact factor: 4.905

7.  CRF-41 stimulates the release of beta-lipotrophin and beta-endorphin in normal human subjects.

Authors:  L McLoughlin; S Tomlin; A Grossman; N Lytras; A V Schally; D Coy; G M Besser; L H Rees
Journal:  Neuroendocrinology       Date:  1984-04       Impact factor: 4.914

8.  Stimulation of adrenocorticotropin/beta-endorphin release by synthetic ovine corticotropin-releasing factor in vitro. Enhancement by various vasopressin analogs.

Authors:  W Knepel; L Homolka; M Vlaskovska; D Nutto
Journal:  Neuroendocrinology       Date:  1984-05       Impact factor: 4.914

9.  Effects of synthetic corticotropin-releasing factor in normal individuals and in patients with hypothalamic-pituitary-adrenocortical disorders.

Authors:  H Jørgensen; S Skare; H Frey; K F Hanssen; N Norman
Journal:  Acta Med Scand       Date:  1985

10.  The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome.

Authors:  G P Chrousos; H M Schulte; E H Oldfield; P W Gold; G B Cutler; D L Loriaux
Journal:  N Engl J Med       Date:  1984-03-08       Impact factor: 91.245

View more
  2 in total

1.  Use of quantitative ultrasound of the hand phalanges in the diagnosis of two different osteoporotic syndromes: Cushing's syndrome and postmenopausal osteoporosis.

Authors:  V Camozzi; V Carraro; M Zangari; F Fallo; F Mantero; G Luisetto
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

2.  Intravenous dexamethasone and subsequent ACTH test in comparison with dexamethasone oral test in the diagnosis of Cushing's syndrome: a report of 20 cases.

Authors:  S Gambardella; G Tamburrano; A Giaccari; S Frontoni; A Lala; V Spallone; A Barini; M G Felici; G Menzinger
Journal:  J Endocrinol Invest       Date:  1989-03       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.